The research compound in Alli®
Alli® is a weight management (over the counter) medicine from GlaxoSmithKline. Its active compound is Orlistat — which is what this catalogue supplies, as a research material.
This is not Alli®, and NOVALYTE LABS has no affiliation with GlaxoSmithKline. We supply the compound Orlistat for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Alli® is a trademark of GlaxoSmithKline, referenced here only to identify the compound.
Alli is the lower-dose, over-the-counter presentation of orlistat, the same compound sold on prescription as Xenical.
Orlistat inhibits pancreatic lipase in the gut, acting locally on fat absorption rather than systemically on appetite.
The compound is listed here as a research material with batch documentation.
Orlistat in this catalogue
120mg oral tablets
How Orlistat is supplied here
Everything below describes the research material in this catalogue, not the medicine.
| Compound | Orlistat |
|---|---|
| Presentation | 120mg oral tablets |
| Dosage options | 120mg |
| Research category | Metabolic Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Alli?
Orlistat. Alli is a registered trademark of GlaxoSmithKline, approved for weight management (over the counter).
Is this Alli?
No. NOVALYTE LABS supplies Orlistat as a research material with batch documentation. It is not Alli, it is not a medicine, it is not supplied for human use, and there is no affiliation with GlaxoSmithKline.
Why is Orlistat sold under more than one brand?
Because a brand is tied to an approved indication rather than to the molecule. Orlistat is marketed as Alli and also as Xenical — same compound, different approvals.
Other brands using Orlistat
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.